Roselabs Finance

Why is Roselabs Finance Ltd falling/rising?

As of 01-Aug, Roselabs Finance Ltd's stock price is stable at 23.00, but it has underperformed compared to the market, with a troubling long-term outlook marked by negative returns and financial health concerns. Despite recent short-term gains, the stock's fundamentals suggest it is a risky investment.

As of 01-Aug, Roselabs Finance Ltd's stock price is currently stable at 23.00, showing no change (0.00%). However, the stock has been underperforming compared to the broader market and its sector. Over the past week, the stock has increased by 1.55%, but this is significantly lower than the Sensex's gain of 2.68%. In the last month, the stock has performed better with a rise of 12.20%, while the Sensex only increased by 1.52%. <BR><BR>Despite these short-term gains, the stock has a troubling long-term outlook. Year-to-date, it has risen by 11.70%, contrasting sharply with the Sensex's decline of 8.36%. However, over the past year, Roselabs Finance Ltd has seen a significant drop of 17.53%, while the benchmark has only fallen by 3.81%. This consistent underperformance over the last three years, where the stock has generated negative returns, indicates a weak long-term fundamental strength.<BR><BR>Additionally, the company is facing challenges such as a negative book value and a negative EBITDA of Rs. -0.2 crore, which raises concerns about its financial health. The recent flat results reported on June 26 and a decline in investor participation, with delivery volume dropping by 98.51% against the 5-day average, further suggest a lack of confidence among investors. <BR><BR>Overall, while there have been some short-term gains, the long-term fundamentals and recent performance metrics indicate that Roselabs Finance Ltd is facing significant challenges, contributing to its overall perception as a risky investment.

Which are the latest news on Roselabs Finance?

Should I buy, sell or hold Roselabs Finance Ltd?

How big is Roselabs Finance?

As of 10th June, Roselabs Finance Ltd has a market capitalization of 22.00 Cr and reported Net Sales of 1.21 Cr, with a Net Profit loss of 0.31 Cr over the latest four quarters. As of March 2025, Shareholder's Funds were at a loss of 4.73 Cr, and Total Assets were 0.12 Cr.

As of 10th June, Roselabs Finance Ltd has a market capitalization of 22.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Roselabs Finance reported Net Sales of 1.21 Cr. However, the company experienced a loss of 0.31 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds were recorded at a loss of 4.73 Cr, and Total Assets amounted to 0.12 Cr.

Who are in the management team of Roselabs Finance?

The management team of Roselabs Finance includes Sanjyot Rangnekar (Chairperson), Prakash Lavji Vaghela and Mayank Padiya (Non-Executive & Independent Directors), Abhijeet Shinde (Company Secretary & Compliance Officer), and Raghava Reddy Balineni (Managing Director).

The management team of Roselabs Finance includes the following individuals:<BR><BR>1. **Sanjyot Rangnekar** - Chairperson<BR>2. **Prakash Lavji Vaghela** - Non-Executive & Independent Director<BR>3. **Mayank Padiya** - Non-Executive & Independent Director<BR>4. **Abhijeet Shinde** - Company Secretary & Compliance Officer<BR>5. **Raghava Reddy Balineni** - Managing Director<BR><BR>If you need more specific information about their roles or contributions, feel free to ask!

Who are the peers of the Roselabs Finance?

Peers of Roselabs Finance include Jindal Capital, Swarna Securitie, Easun Capital Ma, Smart Finsec, Mansi Fin.(Chen), GSB Finance, Helpage Finlease, KJMC Corporate, and Shree Metalloys. GSB Finance has the highest 1-year return at 30.45%, while Smart Finsec has the lowest at -43.34%, with Roselabs Finance at -36.42%.

Peers: The peers of Roselabs Finance are Jindal Capital, Swarna Securitie, Easun Capital Ma, Smart Finsec, Mansi Fin.(Chen), GSB Finance, Helpage Finlease, KJMC Corporate, and Shree Metalloys.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jindal Capital, Easun Capital Ma, Smart Finsec, Mansi Fin.(Chen), GSB Finance, Helpage Finlease, and KJMC Corporate, while Below Average management risk is found at Shree Metalloys and the rest. Growth is Excellent at Helpage Finlease, Good at KJMC Corporate, and Average at Shree Metalloys, while Below Average growth is noted for Jindal Capital, Easun Capital Ma, Smart Finsec, Mansi Fin.(Chen), GSB Finance, and the rest. Excellent capital structure is seen at Jindal Capital, Easun Capital Ma, Smart Finsec, Mansi Fin.(Chen), GSB Finance, Helpage Finlease, and KJMC Corporate, while Good capital structure is found at Shree Metalloys, and the rest do not qualify.<BR><BR>Return Snapshot: GSB Finance has the highest 1-year return at 30.45%, while Smart Finsec has the lowest at -43.34%, with Roselabs Finance's own 1-year return at -36.42% being higher than Smart Finsec's but lower than GSB Finance's. Additionally, peers with negative six-month returns include Jindal Capital, Easun Capital Ma, Smart Finsec, Mansi Fin.(Chen), and Dynamic Portfol.

What does Roselabs Finance do?

Roselabs Finance Ltd is a Micro Cap NBFC that primarily engages in non-banking finance. As of March 2026, it reported net sales and profit of 0 Cr, with a market cap of INR 22 Cr.

Overview:<BR>Roselabs Finance Ltd operates in the Non-Banking Financial Company (NBFC) sector and is categorized as a Micro Cap company.<BR><BR>History:<BR>Incorporated on 4th January, 1995, Roselabs Finance Limited initially engaged in Non-Banking Finance. In 2012-13, it became a direct subsidiary of Arihant Premises Private Limited and a step down subsidiary of Lodha Developers Private Limited, effective from 10th June, 2013. The latest reported quarter for sales and profit is March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2026)<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 22 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 20<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -1.02<BR>Return on Equity: 6.42%<BR>Price to Book: -4.55<BR><BR>Contact Details:<BR>Address: 412 4th Flr 17G Vardhaman Cham, Cawasji Patel Road Fort Mumbai Maharashtra : 400001<BR>Email: roselabsfinance@lodhagroup.com<BR>Website: http://www.roselabsfinancelimited.in

Are Roselabs Finance Ltd latest results good or bad?

Roselabs Finance Ltd's latest results are concerning, showing a net profit of ₹-0.16 crores and no revenue generation in Q4 FY26, indicating significant financial struggles and a negative book value per share of ₹-4.73. Overall, these indicators suggest the company is facing serious viability challenges.

The latest results for Roselabs Finance Ltd are quite concerning. In Q4 FY26, the company reported a net profit of ₹-0.16 crores, which reflects a significant deterioration compared to the previous quarter's loss of ₹-0.04 crores. This represents a staggering QoQ decline of 300%. Furthermore, net sales for the quarter were ₹0.00 crores, indicating a complete absence of revenue generation and a 100% decline year-over-year.<BR><BR>The company's financial health is further highlighted by its negative book value per share of ₹-4.73, which signifies that shareholder equity has been entirely eroded. Additionally, the return on capital employed (ROCE) stands at a troubling -31.00%, indicating poor capital efficiency.<BR><BR>Overall, these results suggest that Roselabs Finance is struggling significantly, with no meaningful operational activity and persistent losses. The financial indicators point to a company that may be facing serious viability challenges, making the latest results decidedly bad.

Is Roselabs Finance overvalued or undervalued?

As of December 4, 2025, Roselabs Finance is considered very attractive and undervalued compared to its peers, with a PE Ratio of -75.86 and a year-to-date return of -37.11%, indicating that the market has not fully recognized its potential.

As of 4 December 2025, the valuation grade for Roselabs Finance has moved from risky to very attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued, especially given its headline ratios, which include a PE Ratio of -75.86, an EV to EBIT of -26.94, and a PEG Ratio of 0.00. These figures suggest that the market is not fully recognizing the potential of Roselabs Finance, particularly in comparison to its peers.<BR><BR>In the peer comparison, Bajaj Finance is categorized as very expensive with a PE Ratio of 34.9, while Life Insurance is very attractive with a PE Ratio of 10.85. This stark contrast highlights the undervaluation of Roselabs Finance within its industry. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -37.11% compared to the Sensex's 9.12%, further reinforcing the notion that the market has not yet adjusted to the company's improved valuation outlook.

How has been the historical performance of Roselabs Finance?

Roselabs Finance has experienced a gradual increase in net sales, reaching 0.71 Cr in March 2025, but reported losses in operating profit, profit before tax, and profit after tax of -0.29 Cr. The company faces ongoing financial challenges, with negative reserves and stagnant cash flow.

Answer:<BR>The historical performance of Roselabs Finance shows a gradual increase in net sales, reaching 0.71 Cr in March 2025, up from 1.14 Cr in March 2024, and starting from zero in the previous years. The total operating income followed a similar trend, with a peak of 1.14 Cr in March 2024 and a slight decline in March 2025. The company has consistently reported no raw material costs or purchases of finished goods, indicating minimal operational activity. Employee costs have increased slightly from 0.05 Cr in March 2024 to 0.06 Cr in March 2025. Manufacturing expenses peaked at 1.13 Cr in March 2024 but decreased to 0.70 Cr in March 2025. Total expenditure, excluding depreciation, was 1.02 Cr in March 2025, down from 1.31 Cr in March 2024. Operating profit (PBDIT) showed a loss of -0.29 Cr in March 2025, worsening from -0.13 Cr in March 2024. Profit before tax also reflected losses, with -0.29 Cr in March 2025 compared to -0.13 Cr in March 2024. The profit after tax mirrored this trend, resulting in -0.29 Cr in March 2025. The company's reserves have been negative, standing at -14.73 Cr in March 2025, indicating ongoing financial challenges. The book value per share adjusted to -4.73 in March 2025, reflecting a decline from -4.44 in March 2024. Cash flow activities have remained stagnant, with no cash inflow or outflow reported across the years.<BR><BR>Breakdown:<BR>Roselabs Finance's financial performance has shown a modest increase in net sales, reaching 0.71 Cr in March 2025, although it declined from the previous year's 1.14 Cr. The total operating income also decreased slightly to 0.71 Cr in March 2025. The company has maintained no raw material or finished goods purchases, with employee costs rising marginally to 0.06 Cr. Manufacturing expenses decreased significantly from 1.13 Cr in March 2024 to 0.70 Cr in March 2025, contributing to a total expenditure of 1.02 Cr in March 2025. Operating profit (PBDIT) reflected a loss of -0.29 Cr, worsening from -0.13 Cr in the prior year, while profit before tax and profit after tax both reported losses of -0.29 Cr. The company's reserves have remained negative, indicating financial strain, with a book value per share of -4.73 in March 2025. Overall, the cash flow situation has been stagnant, with no reported cash movements over the years.

When is the next results date for Roselabs Finance?

The next results date for Roselabs Finance is 18 July 2025.

The next results date for Roselabs Finance is scheduled for 18 July 2025.

What is the technical trend for Roselabs Finance?

As of June 4, 2025, Roselabs Finance shows a mildly bearish trend overall, influenced by daily moving averages and a monthly MACD, despite mixed signals from the weekly MACD and other indicators.

As of 4 June 2025, the technical trend for Roselabs Finance has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The daily moving averages are mildly bearish, reinforcing the current bearish trend. The Bollinger Bands show a sideways movement on the weekly chart but are mildly bullish on the monthly chart, indicating potential volatility. The KST and OBV are both mildly bullish on the weekly, but the monthly KST is mildly bearish, which adds to the uncertainty. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

Who are the top shareholders of the Roselabs Finance?

The top shareholder of Roselabs Finance is Macrotech Developers Limited, holding 74.25% of the shares. Other significant shareholders include Arhanathji Builders And Farms Pvt Ltd at 4.96% and individual investors with a collective 15.15%.

The top shareholders of Roselabs Finance are primarily the promoters, with Macrotech Developers Limited holding the largest share at 74.25%. There are no pledged promoter holdings, and currently, there are no mutual funds or foreign institutional investors involved. The highest public shareholder is Arhanathji Builders And Farms Pvt Ltd, which holds 4.96%. Additionally, individual investors collectively hold 15.15% of the shares.

Has Roselabs Finance declared dividend?

No Dividend History Available